ArticlePathology oncology research : POR2020
Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations.
Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Subtype-Specific Metabolic Patterns in Staging Breast Cancer: Insights from Conventional and Parametric PET Radiomics.Cancers · 2026Article
- Modelling image quality over extended [Frontiers in oncology · 2026Article
- Dual-phase multiobjective Bayesian optimization method for estimating hepatocellular carcinoma dynamics parameters from PET/CT scans.Quantitative imaging in medicine and surgery · 2025Article
- Model selection for dynamic PET compartmental modelling ofEJNMMI research · 2025Article
- Dynamic profiles of early biological responses to predict the treatment efficacy of proton therapy in liver cancer assessed with in vivo kinetic [18F]-FDG PET/MRI.Radiation oncology (London, England) · 2025Article
- Dynamic FDG PET/CT imaging: quantitative assessment, advantages and application in the diagnosis of malignant solid tumors.Frontiers in oncology · 2025Review
- Increased lesion detectability in patients with locally advanced breast cancer-A pilot study using dynamic whole-body [EJNMMI research · 2024Article
- KineticEJNMMI physics · 2024Article
- Evaluation of blood supply and metabolism in tumor, axillary lymph node and normal breast tissue with F-18 FDG PET/CT in breast cancer: comparison with pathological prognostic factors.BMC women's health · 2024Article
- Evaluating the correlation between pretreatmentPathology oncology research : POR · 2024Article
- Quantitative parameters of static imaging and fast kinetics imaging inQuantitative imaging in medicine and surgery · 2023Article
- Value of DynamicMolecular imaging and radionuclide therapy · 2023Article
- Tumor infiltrating lymphocytes and radiological picture of the tumor.Medical oncology (Northwood, London, England) · 2023Review
- The Relationship between Pathological Features andWorld journal of nuclear medicine · 2022Article
- Improved Clinical Workflow for Whole-Body Patlak Parametric Imaging Using Two Short Dynamic Acquisitions.Frontiers in oncology · 2022Article
- Dynamic FDG-PET imaging for differentiating metastatic from non-metastatic lymph nodes of lung cancer.Frontiers in oncology · 2022Article
- Relationship of the standard uptake value ofScientific reports · 2021Article
- Pretherapeutic Imaging for Axillary Staging in Breast Cancer: A Systematic Review and Meta-Analysis of Ultrasound, MRI and FDG PET.Journal of clinical medicine · 2021Review
- Use of population input functions for reduced scan duration whole-body PatlakEJNMMI physics · 2021Article
- Correlation BetweenFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our aim was to evaluate correlation between clinicopathological features (clinical T and clinical N stages; histological type; nuclear grade; hormone-receptor and HER2 status, proliferation activity and tumor subtypes) of breast cancer and kinetic parameters measured by staging dynamic FDG-PET/CT examinations. Following ethical approval and patients' informed consent we included 34 patients with 35 primary breast cancers in our prospective study. We performed dynamic PET imaging, and assessed plasma activity noninvasively. To delineate primary tumors we applied a frame-by-frame semi-automatic software-based correction of motion artefacts. FDG two-compartment kinetic modelling was applied to assess K1, k2, k3 rate coefficients and to calculate Ki (tracer flux constant) and MRFDG (FDG metabolic rate). We found that k3, Ki and MRFDG were significantly higher in higher grade (p = 0.0246, 0.0089 and 0.0076, respectively), progesterone-receptor negative (p = 0.0344, 0.0217 and 0.0132) and highly-proliferating (p = 0.0414, 0.0193 and 0.0271) tumors as well as in triple-negative and hormone-receptor negative/HER2-positive subtypes (p = 0.0310, 0.0280 and 0.0186). Ki and MRFDG were significantly higher in estrogen-receptor negative tumors (p = 0.0300 and 0.0247, respectively). Ki was significantly higher in node-positive than in node-negative disease (p = 0.0315). None of the assessed FDG-kinetic parameters showed significant correlation with stromal TIL. In conclusion, we confirmed a significant relationship between kinetic parameters measured by dynamic PET and the routinely assessed clinicopathological factors of breast cancer: high-grade, hormone-receptor negative tumors with high proliferation rate are characterized by higher cellular FDG-uptake and FDG-phosphorylation rate. Furthermore, we found that kinetic parameters based on the dynamic examinations are probably not influenced by stromal TIL infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.